Immediate Impact
9 standout
Citing Papers
Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
2024 Standout
Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks
2024 Standout
Works of Emanuela Pozzi being referenced
Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study
2020
Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy
2016
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Emanuela Pozzi | 47 | 37 | 26 | 5 | 89 | |
| Dan Christian Chiforeanu | 45 | 20 | 52 | 5 | 88 | |
| Franciszek Szubstarski | 60 | 75 | 17 | 8 | 97 | |
| Bryn Pressnail | 62 | 57 | 59 | 5 | 157 | |
| David M. Roy | 23 | 66 | 29 | 5 | 163 | |
| Amy Garrett | 34 | 36 | 13 | 6 | 93 | |
| C. Ang | 35 | 26 | 31 | 5 | 101 | |
| Stacey Green | 16 | 17 | 52 | 4 | 73 | |
| Dahlia Henry | 47 | 62 | 9 | 7 | 109 | |
| Toshitsugu Okayama | 30 | 26 | 9 | 7 | 111 | |
| Marie-Paule Sablin | 45 | 62 | 13 | 4 | 132 |
All Works
Loading papers...